IRIX

Iridex

1.16

0.03+2.65%

Opening15:02 08/18 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE1.110/1.130

TODAY RANGE1.110-1.220

VOL85.93K

MARKET CAP19.71M

52 WEEK RANGE0.7820-2.140

AVG VOL (3M)114.66K

% TURNOVER0.51%

TURNOVER--

P/E (TTM)-2.6852

% RANGE9.76%

EPS(TTM)-0.4320

P/E(FORWARD)-2.2308

P/B2.842

BVPS0.4081

DIVIDEND--

P/S0.3965

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP13.99M

SHARES OUTSTANDING16.99M

NEXT EARNINGS11/03-11/07

FREE FLOAT12.06M

LOT SIZE1

EX-DATE--

News

Press Releases

Financial Reports

Profile

TipRanks·5d ago
Iridex Reports Revenue Growth and Expense Reduction in Q2 2025
Seeking Alpha·5d ago
Iridex outlines further cost reductions and targets profitability in 2025 as Q2 revenue rises 14% sequentially
Benzinga·5d ago
CORRECTION: Iridex Q2 EPS $(0.06) Misses $0.06 Estimate, Sales $13.57M Up From $12.63M YoY
Dow Jones·5d ago
*Iridex: Plans to Achieve Cash Flow Breakeven and Positive Adjusted EBITDA in 2025 on Rev Generation Consistent With 2024 >IRIX
Benzinga·5d ago
Iridex Q2 EPS $0.06, Inline, Sales $13.60M Up From $12.63M YoY
Seeking Alpha·5d ago
IRIDEX GAAP EPS of -$0.06, revenue of $13.6M
Benzinga·5d ago
Iridex Q2 Sales $13.60M Up From $12.63M YoY
Reuters·5d ago
IRIDEX Corporation Reports 7% YoY Revenue Growth in Q2 2025; Achieves Positive Adjusted EBITDA
Barchart·6d ago
Iridex: Q2 Earnings Snapshot
Reuters·07/29 20:05
IRIDEX Corporation to Release Second Quarter 2025 Financial Results
Reuters·07/29 15:00
Iridex Biometrics ASA Announces Private Placement of 9.09 Million Shares at NOK 3.30 Each
Benzinga·07/24 21:06
12 Health Care Stocks Moving In Thursday's After-Market Session
TipRanks·06/24 11:05
Iridex announces first patient enrolled in investigator-led study of MicroPulse
Reuters·06/24 11:00
IRIDEX ANNOUNCES FIRST PATIENT ENROLLED IN AN INDEPENDENT LANDMARK INVESTIGATOR-LED UK STUDY EVALUATING MICROPULSE® TECHNOLOGY AS AN ADJUNCT TO ANTI-VEGF THERAPY FOR DIABETIC MACULAR EDEMA
TipRanks·05/22 20:59
Iridex Amends Investor Rights Agreement with Novel

Same Industry

Name/Symbol

Change%

Price

Iridex

IRIX

+2.65%

1.16

Thermo Fishr Sci

TMO

+0.25%

490.24

Waters

WAT

-0.43%

290.30

Danaher Corporation

DHR

-0.41%

210.06

Fulgent Genetics

FLGT

+1.36%

21.55

Resmed

RMD

+0.57%

286.51

Check Point Software Tech Ltd

CHKP

-0.40%

188.16

Agilent Technologies Inc

-0.36%

118.77

Abiomed Inc

ABMD

0.00%

381.02

Ge Healthcare Technologies Inc

GEHC

+0.03%

73.43

Intuitive Surgical Inc

ISRG

-0.04%

480.06

Veeva Sys Inc

VEEV

+1.66%

285.27

Revvity Inc

RVTY

-0.88%

89.98

Edwards Lifesciences Corp

+0.38%

78.56

Inmode Ltd.

INMD

+0.03%

14.36

athenahealth

ATHN

0.00%

10.01

Bruker Corp

BRKR

+2.37%

34.32

VARIAN MEDICAL

VAR

0.00%

0.0000

Integer Hldgs Corp

ITGR

-1.20%

105.51

Hologic Inc

HOLX

-0.19%

67.68

Quidel

QDEL

+0.76%

26.13

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Contact Number : +852 3852 8500Service Email : service@webull.hkBusiness Cooperation : marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English